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SUMMARY
Clinical guidelines specify sequences of steps (care pathways) to treat patients with single conditions.
Increasingly many patients exhibit ‘multimorbidity’, several chronic conditions needing concurrent
treatment. However, applying multiple guidelines in parallel can lead to conflicts, e.g. between prescribed
drugs, lifestyle intervention recommendations, or treatment schedules. In computer science, process
languages used to design and reason about software development and business process management are
similar to clinical pathways. Using formal model transformation, composition and analysis methods, models
can be combined and conflicts detected and resolved. We propose BPMN+V, a data-driven formal model for
clinical care pathways, as an extension of BPMN. We describe a method for conflict detection using a
transformation of BPMN+V to Coloured Petri Nets, and a state-space method for detection of conflict in
composed models. We present results from a case study, showing that common conflicts are successfully
detected, and propose extension to a complete framework for efficiently recommending resolutions to
medical conflicts in composed care pathway models. Copyright c© 2017 John Wiley & Sons, Ltd.
Received . . .
KEY WORDS: BPMN, Workflow models, Coloured Petri Nets, Model Transformation, Clinical
Guidelines, Care Pathways, Conflict Detection, Multimorbidity
1. INTRODUCTION
The Business Process Model and Notation [1] (BPMN) is the de facto and also ISO† standard [2] for
process modelling, providing support for modelling control flow, data flow and resource allocation.
BPMN’s intuitive graphical model [3] is particularly suitable for capturing business processes by
domain experts who may not have development skills [4, 5, 6]. The ability to handover BPMN
specifications to automatically assist execution via languages such as Business Process Execution
Language (BPEL [7]) reduces the time and cost from the design of a business process to its
production. As a result, BPMN is widely adopted [8] within industry‡ and via various open source
Business Process Management (BPM) tools. BPMN has been widely used in various application
domains [9], including government [10], software development [11] and service management [12],
construction [13], education [14], and healthcare (e.g. [4, 5, 6, 15, 16, 17]).
Clinical guidelines document the best available evidence for care of patients with specific medical
conditions (‘morbidities’). In the United Kingdom (UK) they are used in combination with national
guidance and local National Health Service (NHS) policy to provide appropriate care in a local
∗Correspondence to: Philip Weber, School of Computer Science, University of Birmingham, B15 2TT, UK. Email:
dr.philip.weber@ieee.org
Contract/grant sponsor: EPSRC; contract/grant number: EP/M014401/1
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‡E.g. SAP (https://go.sap.com/), IBMWebsphere (https://www.ibm.com/software/websphere/).
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context. Guidelines have to date been published by the National Institute of Clinical Excellence
[18] for 253 individual morbidities (e.g. Type Two Diabetes Mellitus [19] and Chronic Obstructive
Pulmonary Disease (COPD) [20]). Flowchart-style care pathways can be generated from these
guidelines and have been found to improve patient outcomes [21]. These are informal in the sense
that they are not endowed with a rigorous mathematical semantics.
Patients with multiple concurrent chronic conditions (referred to as ‘multimorbidity’) are rapidly
rising in prevalence in the UK [22]. Guidance relating to the management of these patients is limited
[23, 24], since guidelines focus on single morbidities, and when new treatments or interventions are
assessed for effectiveness within a clinical trial setting, co-morbidities are excluded where possible
to limit confounding the findings. Therefore it is challenging to form guidance tailored to a patient
as an individual, rather than focussed on each clinical condition in isolation [25, 26]. In this work
we investigate extending BPMN to model medical guidelines, as a vehicle for studying in a patient-
focussed manner the interactions between treatments or interventions when the patient is suffering
from multiple morbidities.
BPMN models are analysable, and suitable restrictions of the notation can be endowed with
a strong mathematical semantics (e.g. [27, 28, 29, 30, 31, 32]). Most research has focused on the
control flow aspects of BPMN, whereas analysis of data flow aspects of BPMN is a less studied topic
— in BPMN the semantics of handling data remain unspecified and open to interpretation [33, 34].
In recent years modelling of data objects and mapping them to Petri nets has received considerable
attention (e.g. [33, 35]): such research paves the way for analysis of BPMN models. However,
to the best of our knowledge existing research focuses on single BPMN models. We address the
question of detecting execution paths in two BPMN models which violate (or not) a set of logical
constraints. For example, consider two BPMNmodels that represent two medical guidelines applied
concurrently to a given patient. Medications are often prescribed through both pathways, but some
of these medications cannot be prescribed simultaneously. How can we automatically detect the
execution paths (treatment steps) that can use a combination of drugs with minimal conflict?
We present a method for detecting execution paths in two BPMN models that violate a given
set of constraints. The outline of our approach is as follows: Firstly, we propose a data-enriched
subset of BPMN, named BPMN+V, appropriate for modelling clinical guidelines and based on
the Workflow Graphs proposed by Vanhatalo et al. [36]. Extending the semantics of Workflow
Graphs to include data models, we obtain a data-rich execution semantics for our subset of BPMN.
Secondly, we outline a transformation from BPMN+V to Coloured Petri Nets (CPN) [37] which
provide a formalisation of BPMN+V to facilitate analysis. Thirdly, CPN models corresponding to
two guidelines are composed and enhanced with logical constraints representing potential conflicts,
such as drug incompatibility, between the associated data models. Finally, the state space analysis
properties of CPN (such as deadlock detection) enable detection of conflicts in the composed model.
The paper is organised as follows. After reviewing background material in Section 2, in Section
3 we propose a simple data model for BPMN to facilitate the problem outlined in Section 4, of
detecting conflict between care pathways. We describe the proposed approach in several parts in
Section 5: the data-enriched BPMN model and associated semantics in Section 5.1 and following;
mapping BPMN+V to CPN in Section 5.9; composition of clinical guidelines mapped as CPN,
and detection of conflicts, in Sections 5.10 and 5.11. A case study (Section 2.1) is used to guide
the discussion throughout the paper. The study uses two self-contained fragments of medical
guidelines, for Osteoarthritis and COPD, which demonstrate conflicts between drug and lifestyle
advice interactions. The final evaluation of the case study is in Section 6. Finally, in Section 7 we
outline future research to extend this framework to enable many different types of conflict to be
detected efficiently using logical analysis and constraint solvers such as Alloy [38] or Z3-SMT [39].
2. BACKGROUND
In this section, we present reference material on which our approach builds. We first describe
our case study modelling conflicts between two care pathway fragments. We then give a brief
background on business processes in general and clinical guidelines and care pathways in particular.
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Figure 1. Pathway fragments for COPD (top) and Osteoarthritis (bottom) used in the case study, modelled
as BPMN with annotations describing data interactions (BPMN+V).
Finally we review the Workflow Graph notation proposed by Vanhatalo et al. [36], which can be
viewed as a subset of BPMN notation; and Coloured Petri Nets.
2.1. Case Study
To illustrate the proposed concepts and techniques, we have modelled two clinical care pathway
excerpts using BPMN 2.0 notation [34]. These are illustrated in Fig. 1 and briefly described
here. The review of medication depicted in the models would form part of a 10 minute review
appointment with a General Practitioner (GP) in the UK, for patients with COPD [40] (top)
and Osteoarthritis [41] (bottom). The pathways have been mapped from the NICE guidance as
representative fragments of much larger models describing the treatment of these diseases.
COPD Medication Review: The review takes place only if the patient reports breathlessness. Four
medications (roflumilast, mucolytics, theophylline and corticosteroids) are then reviewed in
parallel, meaning there is no restriction on the order in which the reviews are carried out.
In the case of theophylline, there are further criteria constraining prescription, and plasma
level monitoring needs to be arranged. For corticosteroids, several further process steps
are triggered. First, the reason for the drug requirement is established, then prescription is
arranged within the constraint of keeping dosage as low as possible. Finally, dependent on the
patient’s age, prophylactics may be prescribed with or without monitoring for osteoporosis.
Osteoarthritis Treatment Review: This review proceeds in four stages: assess and then review
core treatments, review pain relief, then review non-pharmalogical treatments. In the first
stage, written information, the exercise plan, and weight loss interventions are reviewed
together (no restriction on the order of the activities). The second stage involves the review
of four treatments (topical capsacin, pain relief, intra-articular injections, and NSAIDs). The
third stage assesses whether further pain relief is required, and indicates considerations if so.
If these pathways are followed concurrently, as when treating a patient diagnosed with both
Osteoarthritis and COPD, then a conflict occurs. The British National Formulary [42] identifies
that corticosteroids, which may be prescribed in the COPD pathway, and non-steroidal anti-
inflammatory drugs (NSAIDs), which may be prescribed for Osteoarthritis, are in conflict. If
Copyright c© 2017 John Wiley & Sons, Ltd. J. Softw. Evol. and Proc. (2017)
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prescribed together they may lead to serious complicating symptoms§. It is therefore of great
importance that such interactions are discovered and avoided. Given that these example pathways
are fragments of much larger care pathways extracted from the clinical guidelines, an automated
method is crucial for doing so, and also for providing resolutions. Conflicts also exist between
theophylline and roflumilast prescription in the COPD model, and potentially between the
dependencies on ‘breathlessness’ in the two models.
2.2. Business Processes
Business processes describe activities carried out to fulfil a business function, and the relations
between them [43], known as ‘control-flow’. Such functions are varied, including service, financial
or customer management, software development, or in healthcare, treatment of patients. Defining
processes facilitates understanding, and managing the complex interactions between activities
and resources can help demonstrate adherence to regulations, or increase efficiency. Various
representational mechanisms have been suggested for capturing process control flow. These range
from formal languages such as Petri nets [44, 45, 46] or BPMN [34] which allow systematic analysis
and comparison, to flowchart notations used to informally discuss business processes, such as the
care guidelines for COPD [40] or Osteoarthritis [41].
Petri nets are widely used to model concurrent and distributed systems, and are rigorously
defined, whereas BPMN although standard and very flexible, is not fully formalised [47]. So-called
Workflow models are therefore now widely used for specifying business processes [46, 48, 49, 50].
These restrict the structure and behaviour of the models to a subset adequate for specifying business
processes with well-defined behaviour and properties for analysis. Focusing on the analysis of the
systems, Van der Aalst et al. [46, 48] present a Workflow modelling language in which models are
constructed from blocks of Petri net models representing common workflow constructs.
2.3. Clinical Guidelines and Care Pathways
Formation of clinical guidelines is complex [51, 52, 53], requiring critical appraisal of evidence
from many sources such as systematic reviews and clinical trials. Care pathways distilled from
the guidelines, used in clinical decision support systems, present as large and complex networks of
many activities, typically broken down into interacting sub-processes (e.g. [40, 41]). Features of care
pathways include steps for assessment, treatment and review, as well as links to related pathways.
Diverse options may be given for treatment and advice to help improve a condition, including for
example lifestyle recommendations, exercise specifications or dietary advice. Care pathways also
detail medication options, prescribing the clinically appropriate medication both for the presenting
complaint and also for prevention of other conditions for which risk factors have been noted.
Another major element within the pathway relates to specialist services referrals, which could be
within secondary- or tertiary-centred care. After being referred, the patient will be under a different
section of the pathway, specific to that healthcare sector. For example, some medications can only
be prescribed under specialist rather than generalist care. All of these decisions will be noted within
the pathway. Furthermore, the decisions have the ability to trigger different sections of the pathway,
creating the need to go back and re-investigate earlier options within the path.
The implementation challenges introduced by such complex processes, and increasing time
pressures within the NHS have promoted the need to look outside the healthcare sector for solutions.
Computer Scientists have investigated novel solutions to problems associated with healthcare
pathways and clinical guidelines [54], for example using string metrics to identify how patient
journeys differ from the prescribed care pathway [55]. This is particularly useful for interrogation
of the patient journey to identify real world management. Natural Language Processing (NLP) has
also been used to help with clinical decision support systems [56], extract information from clinical
guidelines [57] and electronic health records [58], and to test improvement to health such as a
reduction of opioid prescribing [59].
§“Increased risk of gastro-intestinal bleeding and ulceration” [42].
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Figure 2. Main BPMN control-flow structures (left of each column pair), with annotations for BPMN+V
(Section 5.1) and mappings to Coloured Petri Nets (Section 5.9, right of each column pair). Inclusive OR (far
right column) splits are mapped as a combination of parallel and exclusive. Joins are mapped equivalently.
2.4. BPMN for Modelling Clinical Pathways
Many healthcare studies have employed BPMN to model clinical pathways (CPs) [4, 5, 6, 15, 16,
17]. Several authors have investigated the use of BPMN in healthcare [16, 17], and concluded that
it is “sufficiently suitable for the planned modelling and imaging of CPs” [3], and its prevalence is
increasing [16]. Key benefits of BPMN are stated as being graphically clear and appealing [3] and
designed to facilitate communication between non-specialists [4, 5, 6]. BPMN has been criticised
because its semantics are under-specified and models are not guaranteed to be interoperable between
systems [60]. However it provides for extensions [16, 61], for example to use colour to enhance
comprehensibility of complex clinical processes [5]. Formal semantics for subsets of BPMN [34]
have been proposed including via transformation to Petri nets [47] or YAWL¶ [29, 30, 31].
Formalisms such as Petri nets [44, 45, 46] and YAWL [62] do enjoy fully specified semantics,
including (for YAWL) interaction with data. Arguably this is at the expense of the graphical clarity
and interpretability of BPMN. They have also been criticised [60] as too restrictive for modelling
‘real’ business processes. Computer-Interpretable Guidelines (CIGs) have also been developed as
part of clinical decision support systems (DSS) [63], such as PROforma [64], Arden Syntax [65]
and GLIF [66]. DSS provide a complete environment for process automation and decision support,
including comprehensive supporting clinical information. The interaction with data of YAWL and
PROforma et al. is more complex than required for the conflict detection discussed here, and closely
entwined with the process engine and decision support behaviour. Domain-specific languages may
also risk limited acceptance and interoperability issues [67].
Since we are concerned here with modelling clinical guidelines in an accessible and human-
interpretable way rather than process automation, we base our notation on BPMN for the benefits
of widespread acceptance, ease of interpretation and extension described above. We hope that in the
future our methods may be extended to other data-aware or domain-specific modelling languages.
2.5. Workflow Graphs
We find the modelling language suggested by Vanhatalo et al. [36], based on Petri nets, the closest
to the style of BPMN 2.0 or major software development tools such as Oracle JDeveloper‖. Our
model (Section 5.1) builds on their formalism, outlined next.
Definition 1
A Workflow Graph is a graph G = (N,E), with a set of nodes N connected by a set of edges
E ⊆ N ×N . Each node represents an activity or a control-flow construct from the set {START,
STOP, ACTIVITY, FORK, JOIN, DECISION, MERGE}.
¶Yet Another Workflow Language [62].
‖http://www.oracle.com/.
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These relate to the core control-flow elements used in BPMN 2.0 (Fig. 2), with the exclusion of
‘inclusive’ gateways (a large circle O in a diamond), which we define in our formalism (Section
5.1). Small circles indicate START and STOP nodes; rectangles with rounded corners, ACTIVITY
nodes; diamonds containing a large X, DECISION or MERGE; containing a large +, FORK or JOIN.
Notation 1
AWorkflow Graph G is well-formed [47] by definition:
• G has a unique START node iG with a single output edge and no input edges, and a unique
STOP node oG with a single input edge and no output edges;
• each node n ∈ N has a set of input and output edges I(n) ∈ E and O(n) ∈ E;
• each ACTIVITY node has a single input and a single output edge;
• each FORK and DECISION node has a single input edge and two or more outgoing edges; and
• each JOIN and MERGE node has two or more input edges and a single output edge.
An ACTIVITY node models an atomic (indivisible) unit of work. A DECISION node models choice
between alternate sequences of activity following the node (MERGE nodes model the end of the
alternate paths). A FORK node models sequences of activity which may happen in parallel following
the node (JOIN nodes model the end of the parallel paths).
Definition 2
The behavioural semantics of Workflow Graphs is described as a ‘token game’, similar to the
semantics of Petri nets [44, 45]. The flow of tokens through the graph indicates the progress of
instances of the process execution. See Vanhatalo et al. [36] for full definitions.
Notation 2
A state s of a Workflow Graph G = (N,E) is a mapping s : E → N assigning tokens to edges E.
We write s(e) = k to indicate that in state s edge e carries k ∈ N tokens. An execution of node
n ∈ N results in changing the state of G from s to s′, denoted s
n
−→ s′.
Informally, the state s of Workflow Graph G controls which nodes can be executed, while the
semantics describe the change in state resulting from execution of a node. Execution of an node in
G results in the movement of tokens between the edges to capture the flow of actions. An instance
of the process (e.g. treatment review for a given patient) is started by executing the START node iG,
when a single token is added to its output edge O(iG). There is no change to the allocation of tokens
to other edges in the graph. Multiple process instances may be executing concurrently, thus O(iG)
may carry more than one token. Executing the STOP node oG removes a token from its input edge,
denoting completion of the instance. A node n of type {ACTIVITY, FORK, MERGE} can be executed
if each input edge in I(n) has one or more tokens. One token is then removed from each edge in
I(n), and one token is added to each edge inO(n). If n is a DECISION node then a token is removed
from the single I(n), and added to just one output edge in O(n), chosen non-deterministically. If n
is a JOIN node, a single token is removed from one edge in I(n), chosen non-deterministically from
all those bearing one or more tokens, and passed to the single output edge O(n).
2.6. Coloured Petri Nets
Coloured Petri Nets (CPN) [37] are commonly used to model concurrent systems and analyse their
properties, particularly when data is involved. CPN extends the Petri net formalism with high-
level programming language capabilities, enabling definition of data attached to the process and
interaction between data and process behaviour. As such, they are appropriate for our need to
analyse the interaction between multiple processes (care pathways), where process behaviour is
strongly driven by data (patient characteristics).
Definition 3
A Coloured Petri Net is a bi-partite graph specified by a tuple C = (P, T,A,Σ, V, S,G,E, l), where
• P is a finite set of places, T a finite set of transitions such that P ∩ T = ∅, and A ⊆
(P × T ) ∪ (T × P ) a set of directed arcs. N = (P, T,A) is the Petri net structure of C.
Copyright c© 2017 John Wiley & Sons, Ltd. J. Softw. Evol. and Proc. (2017)
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• Σ is a finite set of colour sets describing types of data associated to the net; V is a finite set of
variables taking on these types.
• S : P → Σ allocates colour sets to places.
• G : T → EXPRV describes guards on transitions, defined using logical expressions or
programming constructs, and interacting with data to determine when transitions can execute.
• E : A→ EXPRV describes guards on arcs, providing a data-driven mechanism to control the
flow of tokens through the net.
• I : P → EXPR∅ describes the initial state of the net, in terms of tokens in places.
Notation 3
The behavioural semantics of CPNs are governed by the flow through the net of data-enriched
coloured tokens, which are associated with variables in V , controlled by the interaction of V with
the types S of places and guard expressions G on transitions and E on arcs.
We use a subset of CPN to formalise our data-enriched BPMN (BPMN+V). We introduce some
CPN concepts as necessary in later sections, and refer the interested reader to Jensen and Kristensen
[37] for full definitions of the syntax and semantics of CPN. Suitably restricted subsets of BPMN
and Petri nets can be defined with equivalent semantics, and a model transformation between
them has been defined by Dijkman et al. [47]. We base a similar transformation on this, between
BPMN+V and CPN, outlined in Section 5.9. CPN have been used as the formal target model for the
underlying semantics of other models of concurrency, such as Sequence Diagrams (e.g. [68]).
3. A SIMPLE DATA MODEL FOR BPMN
Data is a core asset of any organisation, and plays a key role in business processes, forming the
basis of many decisions. In the care pathway in Fig. 1 the decision to prescribe prophylactics or not
in a COPD patient is taken on the basis of the age of the patient. In BPMN the primary construct
for modelling data within the process flow is the data object element [34, p205]. However, the
semantics of data objects remain unspecified and even left to the interpretation of the modellers
[33, 34]. Moreover, in BPMN the behaviour of data objects is decoupled from the control-flow.
Data aspects of BPMN have received considerable attention recently [69, 70, 71]. Meyer et
al. evaluate business process modelling languages with respect to data modelling and investigate
modification of data by activities, events, gateways and control-flows [69]. They also present a set
of algorithms for extracting such data models [70]. Sun et al. [71] present an elaborate formalism
of the interaction between business processes and databases. They deal with crucial issues such as
isolation, or when the execution of one process or instance must not interfere with that of another.
3.1. Data in Care Pathways
Each clinical guideline contains many tests, recommendations and actions covering all aspects of
patient management for a specific condition. All involve data, whether pertaining to the patient
characteristics, clinical aspects, or the environmental context. These data may guide the ‘flow’ of
the patient through the care pathway (e.g. decisions taken on the basis of age or a blood test), and
may themselves be modified by actions taken (e.g. necessity for further pain relief). For example,
lifestyle advice may include data on minimum duration, frequency, and intensity of exercise, and
depend upon patient age and specific symptoms; dietary advice includes examples; and medication
recommendations depend on the presenting complaint but include consideration of cost and patient
preference, as well as the context (generalist or specialist care) within which care is being provided.
Data-driven decisions and data effects of activities may also trigger different sections of the pathway,
or modify previous data attributes, causing earlier parts of the pathway to be revisited.
3.2. Modelling Care Pathway Data in BPMN
The Workflow Graph subset of BPMN we use for modelling the control-flow structure underling
care pathways, corresponds closely to Workflow nets [36, 47]. It is therefore natural to draw on
Copyright c© 2017 John Wiley & Sons, Ltd. J. Softw. Evol. and Proc. (2017)
Prepared using smrauth.cls DOI: 10.1002/smr
8 P. WEBER, B. FERREIRA, B. BORDBAR, ET AL.
Coloured Petri Net (CPN) concepts to enrich our models with data. The formalism of coloured
tokens carrying data attributes through the model, interacting with data-defined guards on elements
of the net, is appropriate for modelling patients with given characteristics interacting with treatment
activities in a particular clinical context. We assign to each token within a BPMN+V model a colour
in the form of a vector of values, to each node a condition guarding execution of the node, and define
implicit data which may affect the process execution.
Notation 4
Assume a fixed set of d variables X = {x1, . . . , xd} of types T (xi) ∈ {T1, . . . , Tm}. We model the
data associated with a process instance as a d-tuple of valuations V = (ν1, . . . , νd), assigning values
to X as the business process executes and tokens flow through the net.
Data types include {boolean, integer, rational, enumerated (categorical)}. For example, in the
COPD treatment process (Fig. 1) we might use boolean variables to record breathlessness and
prescription of the various medications; enum. to record reasons for corticosteroid prescription and
the age category of the patient; rational for plasma level; and integer for approximate weight.
Remark 1
Since we deal with well-defined models (Notation 1), the set of variables X is fixed and will not
change. Our model is therefore a simplification of CPN.
Notation 5
A condition is a first order logic formula c(·) over variables inX . We define pre and post conditions
on nodes, as guards controlling when a node may be executed or may complete. For convenience
we also define edge conditions equivalent to a pre condition on the following node:
Notation 6
A node condition on node n is a pre-condition pre(n) such that pre(n) = c(·), controlling when
n may be executed, or a post-condition post(n) controlling when n may be considered complete.
We write c(·)  V if the variable valuation V satisfies c(·). For example, if n is an ACTIVITY a
representing a treatment only valid for patients over 55 years of age, and we have a variable xi
indicating patient age in years, then pre(a) would be c(x1, . . . , xd) , (xi > 55).
Notation 7
An edge condition is a convenience when considering nodes with multiple output edges (i.e.
diverging gateways). c(eout) corresponds to the pre-condition of the node following the edge, i.e.
c(eout) = pre(n) | n ∈ N ∧ I(n) = eout.
Notation 8
A data modification is a statement f(·) over variables in X describing the effect on data of the
execution of an activity, e.g. x := x+ 1 or x := False. We loosely define D as the set of all valid
such data modification functions.
Notation 9
Assume that a process interacts with a database D. We consider data in D to be implicit to the
process, involved in defining the control-flow, but unchanged by it. For example, a database of drug
interactions [42] describes constraints on the context in which a drug may be prescribed.
In Section 5.1 we describe an extension of the semantic model of Vanhatalo et al. by describing
the changes in the value of colours as the tokens flow through the (data-enhanced) BPMN+V
model. We believe our method will limit the anomalies between data and semantics (see e.g. [33])
through introducing a clear semantics which marries data and control flow. Explicit modelling of
the interaction between data and control-flow enables a transparent view on how process execution
is constrained by, and affects, patient characteristics, and implicitly depends on external attributes
such as medication interactions and resource scheduling.
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4. PROBLEM DESCRIPTION
The problem we address is that of identifying conflicts between clinical care guidelines when
they are followed concurrently in treating patients with multiple morbidities. Assume that we have
two BPMN+V models M1,M2 representing two guidelines, and these interact with a database D.
Suppose further that each model has a set of relevant variables X1, X2 some of which are shared
between the models. We collect the variables into a setX = {x1, . . . , xd} = X1 ∪X2. For example,
assume these variables represent the medication taken when a patient is treated by two pathways (cf
the example in Section 2.1). If the patient is on medication mi, then the corresponding variable
xi is set True. Knowledge of drug interactions (defined in D) indicates that some combinations of
medication are not permitted. We write this as a constraint over the variables.
Notation 10
Suppose that the medication related to variable xi should never be taken with the the medication
related to xj , we write this as a constraint Cr(x1, . . . , xd) , ¬(xi ∧ xj). We assume that we know
all k possible constraints on interactions between variables in X , C = {C1, . . . , Ck}. Although
conflicts of this type betweenM1 andM2 could be identified by checking the values V assigned to
X against the set of constraints C, it is more useful to pin-point which execution paths in the models
are in conflict. We therefore pose the question in this form:
Question
Given two BPMN+V models M1,M2, variables X and a set of constraints C, identify all pairs of
execution paths which will modify the variables in X so that at least one of the C is violated.
5. APPROACH
Our approach to detecting execution paths in conflict between two or more clinical guidelines
follows several steps, detailed in the following sections:
1. define a process modelling language BPMN+V to capture control flow for clinical guidelines,
and its dependencies and effect on data;
2. translate models described as BPMN+V to CPN to facilitate formal analysis;
3. compose CPN models representing multiple clinical guidelines, adding constraints between
the models; and
4. solve the composed model using CPN state space methods to identify points of conflict such
as deadlocks.
Remark 2
The translation to CPN is not strictly necessary, since the BPMN+V notation is consistent and
complete for our purposes, but it allows us to take advantage of the existing theory of CPN analysis.
Remark 3
This is the first introduction of our method. In the future we plan to replace the CPN analysis with
translation to logical constraints and efficient analysis using SAT and SMT solvers.
5.1. Semantics For BPMN With Data
We extend the Workflow Graph formalism ([36] and Section 2.5) to allow for the flow of data
through the graph, using a form of colour for tokens. Our notion of data is defined in Section 3.2.
We refer to this formalism as BPMN+V.
Definition 4
AWorkflow Graph extended with data (BPMN+V) is a tuple G = (N, l, E,X, pre, post,mod):
• N is a finite set of nodes (BPMN elements);
• l : N → {START, END, ACTIVITY, EXCLUSIVE, INCLUSIVE, PARALLEL} is a relation
assigning each node a fixed type;
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• E ⊆ N ×N is a finite set of edges (sequence flows) connecting nodes;
• X = {X1, . . . , Xd} is a finite set of d variables associated with the process;
• pre : N → C is a set of guards defining node pre-conditions, as defined in Notation 5;
• post : N → C is a set of guards defining node post-conditions; and
• mod : N → D is a set of data modifications enacted by ACTIVITIES.
The execution semantics of BPMN+V are described by the flow of tokens through the model.
Notation 11
Letm : E → {T1, T2, . . .} define a marking defining the state of the process, mapping each edge to
a set of coloured token IDs. |m(e)| defines the number of tokens on edge e ∈ E in state m. Each
token Ti is a pair (ti, Vi), with τ(Ti) = ti an ID unique to process instance i, V(Ti) = Vi a valuation
of the variables X as defined in Notation 4. Executing node n ∈ N changes the state from m to
m′, denoted m
n
−→ m′, as n consumes and produces tokens according to the semantics, and may
modify the values Vi. Execution of a sequence of nodes is indicated bym
∗
−→ m′.
Each instance of a process carries a single coloured token, which may be split by diverging
PARALLEL nodes to describe parallel sequences of activity, and merged by converging PARALLEL
nodes. The colour is synonymous with the assigned data values. The valuations affect process
control flow by interacting with guards (pre and post) on nodes, and may be changed by executing
ACTIVITY nodemod statements, as the business process executes and tokens flow through the net.
Notation 12
In the following, unless otherwise indicated, T denotes a token carrying a d-tuple of valuations
(colour) V before execution of the node under consideration. T ′ denotes the same token following
execution, with possibly modified values V ′.
5.2. START Event
A START event is a node n ∈ N that captures the initialisation of a process instance, by creating
a coloured token T ′ on its unique output edge. For example, a patient may be registered on a
programme of treatment. Any BPMN+V model has exactly one START event. Assume V captures
initial values of all data attributes associated with the process instance to be created, then n can
execute (thus the process instance can start) if pre(n)  V . The effect of executingm
n
−→ m′ is:
1. V ′ = V, and
2. m′(e) =
{
m(e) ∪ {T ′} if e ∈ O(n),
m(e) otherwise.
Note thatm′(e) = m(e) ∪ {T ′} ⇒ |m′(e)| = |m(e)|+ 1.
5.3. END Event
An END event n brings the process to a conclusion, e.g. the patient no longer exhibits symptoms of
the morbidity under consideration. Any BPMN+V model has exactly one END event. n can execute
if ∃T = (t, V ) ∈ m
(
I(n)
)
| pre(n)  V . The effect of executingm
n
−→ m′ is:
1. V ′ = V , and
2. m′(e) =
{
m(e) \ {T} if e ∈ I(n),
m(e) otherwise
Note thatm′(e) = m(e) \ {T} ⇒ |m′(e)| = |m(e)| − 1.
5.4. Sequence Flow
Sequence Flow is represented by an edge e between two nodes, expressing flow of execution and
carrying coloured tokens. Edge e = (a, b) between nodes a, b ∈ N is an output edge of its preceding
node, e ∈ O(a), and an input edge of its following node, e ∈ I(b).
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5.5. ACTIVITY Node
An ACTIVITY node a represents an atomic (indivisible) unit of work to be executed. In a
well-formed BPMN+V model an ACTIVITY has exactly one input sequence flow ein ∈ E, i.e.
I(a) = {ein}, and exactly one output sequence flow eout ∈ E, i.e. O(a) = {eout}. On execution,
a consumes a token T = (t, V ) from ein, and returns T
′ = (t, V ′) on eout, with possibly modified
assignment V ′.
ACTIVITY a is executed if: ∃T = (t, V ) ∈ m(ein) | pre(a)  V .
Execution of a changes the state such thatm
a
−→ m′, where
1. post(a)  V ′, and
2. m′(e) =


m(e) \ {T} if e = ein,
m(e) ∪ {T ′} if e = eout,
m(e) otherwise.
5.6. EXCLUSIVE Gateway
An EXCLUSIVE Gateway b models a decision point in a process. It can be either diverging:
modelling a decision to be followed by one of several sequences of subsequent activity, or
converging: modelling the rejoining of the alternative sequences created by the corresponding
previous diverging EXCLUSIVE gateway.
Diverging: In a well-formed BPMN+V model a diverging EXCLUSIVE gateway b has one input
sequence flow ein ∈ E, such that I(b) = {ein}, and two or more output sequence flows O(b) ⊂
{E \ ein}. b consumes a token T from ein and returns it unmodified to one of its output edges.
The gateway b executes if: ∃T = (t, V ) ∈ m(ein) | pre(b)  V .
Then b is executed,m
b
−→ m′, and there exists a unique eout ∈ O(b) such that:
1. V ′ = V ,
2. c(eout)  V
′, and
3. m′(e) =


m(e) \ {T} if e = ein,
m(e) ∪ {T ′} if e = eout,
m(e) otherwise.
A single output sequence flow can be followed after a diverging EXCLUSIVE Gateway b, subject
to satisfaction of its edge condition (the pre-condition on the next node which will be executed, cf
Notation 7). If the condition of more than one sequence flow after an Exclusive Gateway is satisfied,
|{eout|eout ∈ O(b) ∧ c(eout)  V
′}| > 1, then one output flow is chosen non-deterministically.
Converging: In a well-formed BPMN+V model, a converging EXCLUSIVE gateway b corresponds
exactly to a preceding diverging EXCLUSIVE gateway b′ with p output edges. Therefore b has p
input sequence flows |I(b) ⊂ {E \ eout}| = p. For a given process instance identified by token T
with ID τ(T ) = t, a single edge ein ∈ I(b) can be active (carrying a token with ID t), i.e.
∀ein ∈ I(b), T = (t, V ) ∈ m(ein)⇒ ∀ei ∈ I(b) ∧ ei 6= ein (Ti ∈ m(ei)⇒ τ(Ti) 6= t).
b has one output sequence flow eout ∈ E, such that O(b) = {eout}. b consumes a coloured token
from ein and returns it unmodified to eout.
The gateway b therefore executes if
∃ein ∈ I(b) ∧ T = (t, V ) ∈ m(ein) ∧ ∀ei ∈ I(b) ∧ ei 6= ein ∧ ∀Ti ∈ m(ei) τ(Ti) 6= t.
effectingm
b
−→ m′ such that
1. V ′ = V , and
2. m′(e) =


m(e) \ {T} if e = ein,
m(e) ∪ {T ′} if e = eout,
m(e) otherwise.
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5.7. PARALLEL Gateway
A PARALLEL Gateway b indicates that all output sequence flows will be activated simultaneously.
Diverging: In a well-formed BPMN+V model, a diverging PARALLEL gateway b has one input
sequence flow ein ∈ E, such that I(b) = {ein}, and two or more output sequence flows O(b) ⊂
{E \ ein}. b consumes a token from ein and duplicates it unmodified, to each output edge e ∈ O(b).
The gateway b executes if: ∃T = (t, V ) ∈ m(ein) | pre(b)  V and ∀e ∈ O(b), c(e)  V
′.
Thenm
b
−→ m′ such that:
1. T ′ = T , and
2. m′(e) =


m(e) \ {T} if e = ein,
m(e) ∪ {T ′} ∀e ∈ O(b),
m(e) otherwise.
Converging: In a well-formed BPMN+V model, a converging PARALLEL gateway corresponds
exactly to a preceding diverging PARALLEL gateway b′ with p output sequence flows. Therefore
b has p input sequence flows, |I(b) ⊂ {E \ eout}| = p, and one output sequence flow eout ∈ E, such
that O(b) = {eout}.
Since each input edge of b concludes a particular concurrently executing sequence of activities
following b′, the data assignments Vi carried by tokens Ti = (t, Vi), arriving at b on edges ei ∈ I(b)
for a given process instance, may differ. For b to execute, these assignments must be compatible.
They must then be synchronised to a single assignment V ′ on eout.
Notation 13
Compatible data assignments V1, . . . , Vd on tokens arriving at b are defined with respect to the
assignment Y on tokens leaving b′. Let the data assignments to tokens leaving b′, arriving at b, and
leaving b, be denoted respectively:
• each e′out ∈ O(b
′) carries token S = (t, Y ) and Y = (y1, . . . , yd),
• ej ∈ I(b) carries token T = (t, Vj) and Vj = (ν
j
1
, . . . , ν
j
d), 0 < j ≤ p, and
• eout carries token T
′ = (t, V ′) and V ′ = (ν′
1
, . . . , ν′d).
Then Y, V1, . . . , Vp, V
′ satisfy one of the following three criteria; ∀0 < i ≤ d,
1. ∀0 < j ≤ p, νji = yi; assignment to variable xi is not changed by any parallel path following
b′: we set ν′i = yi;
2. ∃0 < j ≤ p, νji 6= yi ∧ ∀0 < k ≤ p, k 6= j, ν
k
i = yi, assignment to xi is changed on one
parallel path only: we set ν′i = ν
j
i ; or
3. ∃0 < j ≤ p, νji 6= yi ∧ ∃0 < k ≤ p, k 6= j, ν
k
i 6= yi, assignment to xi is changed on more than
one parallel path, the data cannot be synchronised, and the gateway cannot execute.
In the case 1. and 2. the differing data assignments on each input are compatible with each other
and with Y , denoted compat(V1, . . . , Vp, Y ), and can be synchronised by setting the elements of
V ′ as stated. We can relax the condition of equality of assignments to a suitable definition of
approximate equality such as numeric values within some threshold. In case 3. the data have been
changed incompatibly and cannot be synchronised: the gateway cannot execute.
Therefore b can execute when each input sequence flow ein ∈ I(b) has a token with the same ID
and the data assignments are compatible, i.e.
∀ein ∈ I(b) Ti = (t, Vi) ∈ m(ein) ∧ ∀eout ∈ O(b
′) S = (t, Y ) ∈ m(eout) ∧ compat(V1, . . . , Vp, Y ).
b consumes a token from each e ∈ I(b),m
b
−→ m′, and creates a single token on eout, such that:
1. V ′ = (ν′
1
, . . . , ν′d) s.t. ν
′
i are assigned according to compatibility cases 1. and 2. above, and
2. m′(e) =


m(e) \ {Ti} if e ∈ I(b) ∧ Ti = (t, Vi) ∈ m(e),
m(e) ∪ {T ′} if e = eout,
m(e) otherwise.
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5.8. INCLUSIVE Gateway
An INCLUSIVE Gateway b models a decision in a process and can trigger more than one outgoing
sequence flow. An INCLUSIVE gateway can be either converging or diverging. It is a combination
of EXCLUSIVE and PARALLEL gateways; a subset of outgoing sequence flows can be activated
following a diverging gateway, paths that are activated take place in parallel, and all and only those
paths that are activated must be synchronised at the subsequent converging gateway.
Diverging: In a well-formed BPMN+V model, a diverging INCLUSIVE gateway b has one input
sequence flow ein ∈ E s.t. I(b) = {ein}, and two or more output sequence flows O(b) ⊂ {E \ ein}.
b consumes a token from ein and duplicates it unmodified to a subset of its output edgesEO ⊂ O(b).
The gateway b executes if: ∃T = (t, V ) ∈ m(ein) | pre(b)  V . Thenm
b
−→ m′, such that:
1. V ′ = V , and
2. m′(e) =


m(e) \ {T} if e ∈ I(b),
m(e) ∪ {T ′} if e ∈ O(b) ∧ c(e)  V ′,
m(e) otherwise.
Converging: If b is converging, then I(b) ⊂ E and O(b) = {eout}. In a well-formed BPMN+V
model, the subsetEI ⊂ I(b) of input sequence flows to a converging INCLUSIVE gateway, receiving
tokens for a given process instance ID t, must correspond with the subset E′O ∈ O(b
′) of outgoing
sequence flows from the preceding diverging INCLUSIVE gateway on which tokens with ID t were
created. We write Ei ≡ E
′
O iff |EI | = |E
′
O| and
∧∀ei ∈ EI ∃eo ∈ E
′
O, To ∈ m(eo) ∧ τ(To) = t ∧m
∗
−→ m′ ∧ Ti ∈ m
′(ei) ∧ τ(Ti) = t,
∧∀eo ∈ E
′
O ∃ei ∈ EI , Ti ∈ m
′(ei) ∧ τ(Ti) = t ∧m
∗
−→ m′ ∧ To ∈ m(eo) ∧ τ(To) = t.
The gateway b executes if EI ≡ E
′
O, and data assignments carried by tokens on EI are compatible
(Notation 13). Then b consumes a token from each e ∈ EI ,m
b
−→ m′, and a single token is created
on eout, such that:
1. V ′ = (ν′
1
, . . . , ν′d) s.t. ν
′
i are assigned according to compatibility cases 1. and 2. above, and
2. m′(e) =


m(e) \ {Ti} if e ∈ EI ∧ Ti = (t, Vi) ∈ m(e),
m(e) ∪ {T ′} if e = eout,
m(e) otherwise.
5.9. Transformation From BPMN+V to CPN
BPMN+V supports only a subset of the semantics of CPN, similar to the restriction of BPMN
and Petri nets supported by Workflow Graphs. The transformation from BPMN to Petri nets
is complicated by the relatively informal semantics of BPMN and features such as INCLUSIVE
gateways, events and message passing, none of which are directly supported by CPN. However,
many INCLUSIVE gateway structures can be modelled by combinations of EXCLUSIVE and
PARALLEL gateways (e.g. [72, 73]). Events and messages are currently not part of our BPMN+V
specification. We therefore use a subset of the transformations described by Dijkman et al. [47]
for Place-Transition (non-Coloured) Petri nets, to transform the BPMN control structures defined
in the previous sections to CPN structures. We extend them to map BPMN+V conditions and data
modification statements onto CPN transition guards and arc inscriptions, as summarised below.
• START and END events are mapped to a start and end place respectively.
• ACTIVITY nodes map to CPN transitions with pre- and post-places as necessitated by
the surrounding nodes. Associated pre-conditions are mapped to transition guards, post-
conditions and data modifications to inscriptions on the outgoing arcs.
• PARALLEL and EXCLUSIVE gateways map to parallel and exclusive-or (XOR) splits whose
semantics are governed by the appropriate use of CPN places (Fig. 2).
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Figure 3. Parallel composition of two care pathway models.
• INCLUSIVE gateways are modelled using a combination of parallel and exclusive splits,
allowing each sequence of activities following the split to be either executed or bypassed.
5.10. Composition of CPN Models
In this work, we employ a simple parallel composition. This is achieved by preceding the start
places of the two models by a ‘silent’ CPN transition and a new start place, and following the end
places with a second ‘silent’ transition and new end place (Fig. 3). This allows the two models
to be followed simultaneously, simulating a patient following two care pathways. This makes the
simplifying assumption that a patient starts both pathways at the same time, whereas most likely
they would be following one or more pathways when a new one is started. However this approach
ensures maximum overlap between the models and thus for all conflicts to be detected. The method
could be extended to allow models to be connected at any point, to apply to a specific situation.
5.11. Conflict Detection
To support the evaluation of the BPMN+V model, we use state-space analysis [37] techniques
to identify conflicts introduced by the composition of the CPN models. The main purpose is to
demonstrate the suitability of BPMN+V to describe care pathways and allow conflicts to be detected.
To simplify the evaluation, we restrict our attention to three types of conflict, described next in
relation to the artificial care pathway fragments illustrated in Table I.
Data assignment. A type of conflict, or inconsistency within a model, can be created by interaction
between the data valuation V associated with a process instance, and the condition on a
single ACTIVITY a. For example, Table I model (1) will be blocked if the patient is already
prescribed with NSAIDs since ACTIVITY “Prescribe NSAIDs” cannot execute. A resolution
might be to introduce a bypass, as in models (7) and (8).
Single variable. If a pair of ACTIVITIES a, b in eiher a single or pair of models check and modify
the same variable x in similar ways, they may conflict. Models (3) and (4) in Table I for
example check and set ‘breathless’ in opposing ways. Similarly, duplicating prescription of
medication [74, 75, 76, 77] or tests [78, 79, 80] could both adversely affect patient safety and
efficiency of the healthcare practice.
Pairs of variables. If ACTIVITY a has a pre-condition on variable x1 and modifies x2, while
ACTIVITY b has a pre-condition on x2 and modifies x1, they may be in conflict. For example,
two drugs which may not be prescribed together [42]: cf models (5) and (6) in Table I.
Conflict detection proceeds in two phases. We first analyse the individual care pathway models
using the steps described below, to determine inconsistencies preventing either model from
executing under certain data valuations. The models are then composed and the same analysis
applied, excluding tokens with valuations which failed the single models.
1. Identify the d variables X involved in on pre- and post-conditions, and the values V to be
checked or assigned, e.g. condition x < 1 involves variable x and value 1.
2. Create a ‘covering set’ of 2d coloured tokens for which the model needs to be checked. For
each xi ∈ X , construct the pair of valuations νi ∈ V that will satisfy and fail each pre- and
post-condition. E.g. tokens must include both True and False values for conditions x or ¬x;
and with values to satisfy both y > 1 and y ≤ 1, for an integer condition y > 1.
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Table I. Artificially-designed illustrative care pathway fragments to demonstrate conflicts within and
between models (Section 6.1 and results in Table II).
Example Model(s) Description
(1)
Prescribe
NSAIDs
guard:not NSAIDS data:NSAI B	

Single model exhibiting a problem with certain
data settings. Non-steroidal anti-inflammatory
drugs (NSAIDs) are prescribed but should not be
over-prescribed. The associated variable is set to
True on prescription, but checked first to avoid
over-prescription.
(2)
Prescribe
NSAIDs
Prescribe
corticosteroids
guard:not NSAIDS,
not corticosteroids
data:NSA
ﬀﬁﬂﬃ !"#,
BOOL:corticosteroids
guard: $%& '()*+,-
not corticosteroids
data:corticosteroids=true
Single model in which two activities are in conflict.
Both NSAIDs and corticosteroids are prescribed
(in parallel). These drugs should not be prescribed
together nor individually over-prescribed, hence
the guards. (Note that whereas in this illustration,
these guards have been added manually, in reality
they would be automatically discovered, e.g. from
the BNF database [42].)
(3) & (4)
Design and
agree exercise
plan
guard:not breathlessBOOL:breathless
Assess
breathlessness
BOOL:breathless data:breathless=true
Two care pathway fragments which exhibit conflict
when combined. The first model includes
prescription of an exercise plan, which should be
avoided if the patient exhibits breathlessness. The
second model fragment sets a variable indicating
breathlessness, which will be in conflict.
(5) & (6)
Prescribe
NSAIDs
guard:not NSAIDS,
not corticosteroids
data:NSA./012345
6789;<=>?@A,
BOOL:corticosteroids
Prescribe
corticosteroids
BOOL:NSAIDS,
BOOL:corticosteroids
guard: not NSAIDS,
not corticosteroids
data:corticosteroids=true
Two pathway fragments which combine the drug
conflict of example model (2) with between-model
conflict illustrated in example models (3) and (4).
The guards and data modifications of the two
prescription activities prevent the model from
executing.
(7) & (8)
Prescribe
NSAIDs
guard:not NSAIDS,
not corticosteroids
data:NSACDEFGHJK
LMNOPQRSTUV,
BOOL:corticosteroids
Prescribe
corticosteriods
BOOL:NSAIDS,
BOOL:corticosteroids
guard: not NSAIDS,
not corticosteroids
data:corticosteroids=true
An example of one way in which example models
(5) and (6) might be changed to avoid conflict. The
prescription activities can now be bypassed.
However, the conflict detection technique presented
will not discover the potential for conflict between
these activities.
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3. Construct the reachability graph Ri (1 ≤ i < 2
d) of the CPN transformation of the model,
corresponding to each token.
4. Identify dead markings in all Ri, and the corresponding blocked ACTIVITIES, conditions
which failed, and the token data assignment and condition variables which are in conflict.
5. A pair of dead markings linked by common variables indicates that the corresponding
ACTIVITIES conflict. The dead markings result from different paths through the model.
For example, in Table I model (4), one path through leads to “Prescribe NSAIDs” before
“Prescribe corticosteroids”, resulting in the latter being blocked. An alternate path leads to the
two activities in the reverse order, with “Prescribe NSAIDs” being blocked. This will result
in two dead markings connected by the boolean variables ‘NSAIDS’ and ‘corticosteroids’.
6. A single dead marking indicates a conflict due to initial data settings, such as an attempt to
prescribe an already-prescribed medication.
We evaluate this approach in the next section. Section 7 outlines plans for more efficient analysis
and determination of medically-appropriate conflicts.
6. EVALUATION
In this section we describe a three stage empirical evaluation of the modelling language and
approach described in Section 5∗∗. We first apply the approach to artificially-designed care pathway
fragments exhibiting conflicts, to validate that BPMN+V is sufficient and complete for modelling
care pathways, and that the approach for finding conflicts between them is effective. We next
investigate the efficiency and scalability of the method for conflict detection, using large numbers
of randomly-generated synthetic models of various size and complexity, with randomly added
conflicts. Finally we apply our method to the case study (Section 2.1), to show that the known
conflicts between the medical guidelines for COPD and Osteoarthritis are successfully identified.
To facilitate the evaluation we use BPMN annotations with structured text to specify the data
aspects of BPMN+V, as illustrated in Fig. 2. Variables are specified as an annotation to the START
event, ACTIVITY pre-conditions and data modifications are specified by annotations beginning
‘guard:’ and ‘data:’ respectively. We do not specify any post-conditions. These restrictions are not
fundamental and in future work we will develop approaches more friendly to the modeller.
6.1. Artificial Care Pathway Fragments
In Table I we illustrate artificially-designed care pathway fragments to validate the BPMN+V
modelling language and the state space method for conflict detection. These are not intended to
be complete standalone pathways but rather to illustrate realistic conflict situations due to (e.g.)
potential over-prescription [74, 75, 76, 77]. The annotations for data dependencies and modification
have been added manually, whereas in the future such constraints will be automatically discovered
using references such as the British National Formulary [42]. As described in Table I, these models
exhibit various data-related inconsistencies and conflicts between models, explained in Section 5.11.
The results of the conflict detection method are shown in Table II. The ‘Activity’ column indicates
the ACTIVITY a found to be blocked or in conflict. ‘Data’ reports the valuation which caused the
conflict, ‘Initial Data’ the valuation of the initial token. ‘Conflict Model’, ‘Conflict Activity’ and
‘Conflict Data’ list any activities and variables found to be in conflict with a. These being empty
indicates that the conflict is caused by the initial token valuation.
For model (1), we correctly identify that the model will be blocked for a patient who is already
prescribed with NSAIDs. Similarly, Model (2) is blocked when either NSAIDs or corticosteroids are
already prescribed. These activities are also in conflict. Since they occur in parallel, either may occur
first and set the variable indicating prescription of the relevant medication, which conflicts with the
guard on the other activity. A similar situation occurs between ‘roflumilast’ and ‘theophylline’ in the
∗∗Code and results can be found at https://bitbucket.org/uobmitcon/jsep2017.
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Table II. Results of applying the state-space based conflict detection method to artificial models (Table I and
Section 6.1).
Conflict Conflict Conflict
ModelActivity Data Initial Data Model Activity Data
1 Prescribe NSAIDs NSAIDS=True NSAIDS=True
2 Prescribe NSAIDs NSAIDS=True NSAIDS=True
2 Prescribe corticosteroids CS=True CS=True
2 Prescribe NSAIDs CS=True CS=True 2 Prescribe NSAIDs,
Prescribe corticosteroids
NSAIDS
2 Prescribe corticosteroids NSAIDS=True NSAIDS=True 2 Prescribe NSAIDs,
Prescribe corticosteroids
CS
2 Prescribe NSAIDs CS=True CS=False 2 Prescribe corticosteroids NSAIDS
2 Prescribe corticosteroids NSAIDS=True NSAIDS=False 2 Prescribe NSAIDs CS
3 Design and agree exercise plan breathless=True breathless=True
3 Design and agree exercise plan breathless=True breathless=False 4
5 Prescribe NSAIDs NSAIDS=True NSAIDS=True
5 Prescribe NSAIDs CS=True CS=True
6 Prescribe corticosteroids CS=True CS=True
6 Prescribe corticosteroids NSAIDS=True NSAIDS=True
5 Prescribe NSAIDs CS=True CS=False 6 Prescribe corticosteroids NSAIDS
6 Prescribe corticosteroids NSAIDS=True NSAIDS=False 5 Prescribe NSAIDs CS
7 & 8 No conflicts detected
case study COPD example (Fig. 1). Model (3) is correctly identified as blocked when ‘breathless’
is True (exercise should not be prescribed) but although the conflict with the setting of this variable
in model (4) has been detected, it could not be fully identified. Further work is needed to determine
if this is a problem with the implementation of the method, or a feature of this artificial example.
Finally, models (5) and (6) exhibit the same medication conflict as model (2), illustrating that these
conflicts are detected when two care pathways are combined. Models (7) and (8) illustrate that a
recommendation to resolve these conflicts might be to introduce a bypass for these tasks. This could
be implemented as a series of steps to check medication and prescribe only if appropriate, mitigating
the danger of unsafe prescription. For these modified models, no conflicts are detected, raising the
question of whether an extended method is desirable to highlight such potential conflicts.
6.2. Efficiency and Scalability
To investigate the performance of the method for conflict detection we generated pairs of random
models of increasing size and complexity, similarly to the method described for Process Log
Generation [81]. Varying numbers of conflicts were inserted into one or both models. Models
were generated by starting with a START–ACTIVITY–END sequence (e.g. model (1), Table I) and
repeatedly randomly choosing an ACTIVITY to expand, up to a given number of structures in
the target model. The chosen ACTIVITY was randomly replaced with either a sequence of two
ACTIVITIES, an EXCLUSIVE diverging gateway followed by two ACTIVITIES and an EXCLUSIVE
merge, or a PARALLEL gateway followed by two ACTIVITIES and a PARALLEL merge. We
experimented with various probabilities for selection of each type of structure.
Fig. 4 reports statistics collected over 30 models of each type. Figs. 4(a) and 4(b) show that
while the time for processing increases somewhat with the number of activities in any model,
it is particularly sensitive to the amount of parallelism in the model. Fig. 4(b) shows that for
composed models with a large amount of parallel activities in the original models, the time for
conflict detection increases approximately exponentially with the number of structures. This is not
unexpected, since the more activities are in parallel, the faster the size of the state space increases.
(We do not consider models with cycles, so the state space remains finite.)
The COPD and OA examples (Fig. 1) each contain 14 activities. These are formalised from NICE
pathways [40, 41] presented as hierarchies of 5-10 flowcharts of approximately 10 activities each,
suggesting full models could have at least 50 activities. Studies have shown that 16% of adult
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Figure 4. Performance of the state space conflict detection method (Section 6.2) for models of varying size and
complexity, averaged over 30 randomly generated models. Top row (a,b): number of states and time (seconds) for conflict
detection, for models generated with varying probability of creating sequence, XOR or parallel split and join structures.
(0.8, 0.1, 0.1) indicates p(seq) = 0.8, p(xor) = 0.1, p(parallel) = 0.1, etc. Bottom row (c,d): mean time for increasing
numbers of randomly-generated conflicts, in models with mostly sequential structures (low parallelism). Left column
(a,c): statistics for single models. Right column (b,d): statistics for the composed models.
patients have more than one chronic condition [82, 83], increasing to 65% of over 65s with two
or more [84]. Although performance efficiency is thus a potentially serious problem for the state
space method described here, especially since the composed models are inherently parallel, these
results were obtained using a basic state space calculation algorithm. As discussed in Section 7,
we plan to use more efficient logical analysis methods. The suitability of the BPMN+V modelling
language is not affected by these results.
Although many conflicts may exist between models – Dumbreck et al. [77] found that between
89 and 133 drug-drug interactions were possible between the guidelines for three conditions in
combination with up to 11 other co-morbidities – Figs. 4(c) and 4(d) show that the method is less
affected by the numbers of conflicts introduced into the model.
6.3. Case Study
In Table III we report the conflicts automatically identified for the case study introduced in Section
2.1. The top and centre sections report for the OA and COPD models individually; the lower section
for the composed model. In this study we used integer variables for medications instead of boolean,
to indicate the number of times a medication was prescribed.
Copyright c© 2017 John Wiley & Sons, Ltd. J. Softw. Evol. and Proc. (2017)
Prepared using smrauth.cls DOI: 10.1002/smr
AUTOMATED CONFLICT DETECTION BETWEEN MEDICAL CARE PATHWAYS 19
Table III. Results of applying the state-space conflict detection method to the COPD and OA case study
(Sections 2.1 and 6.3). CS abbreviates ‘corticosteroids’, RF ‘roflumilast’ and TH ‘theophylline’.
Conflict Conflict Conflict
ModelActivity Data Initial Data Model Activity Data
OA Agree exercise plan breathless=True breathless=True
OA Prescribe NSAIDs NSAIDS=1.0 NSAIDS=1.0
COPD Prescribe and keep dose ... CS=1.0 CS=1.0
COPD Prescribe RF TH=2.0 TH=1.0
COPD Prescribe TH after successful ... RF=2.0 RF=1.0
COPD Prescribe RF TH=1.0 TH=0.0 COPD Prescribe TH after ... RF
COPD Prescribe TH after successful ... RF=1.0 RF=0.0 COPD Prescribe RF TH
OA Prescribe NSAIDs NSAIDS=1.0 NSAIDS=1.0 COPD
COPD Prescribe and keep dose ... CS=1.0 CS=1.0 OA
OA Prescribe NSAIDs CS=1.0 CS=1.0 COPD Prescribe and keep ... NSAIDS
COPD Prescribe and keep dose ... NSAIDS=1.0 NSAIDS=1.0 OA Prescribe NSAIDs CS
For OA and COPD the data valuations which would block the model were correctly identified,
namely the parallel ACTIVITY “Agree exercise plan” in OA is blocked if the patient reports
breathlessness, and NSAIDs cannot be prescribed if already being taken. Similarly for COPD, the
activities to prescribe theophylline and roflumilast block execution of the model if the patient is
already taking these medications. Theophylline and roflumilast may not be taken together, and this
conflict within the COPD model was also discovered correctly.
To obtain a meaningful analysis of the composed model we removed the ‘breathless’ constraint
from OA, since if True it blocks the OA part of the model, while if False, the COPD model is
bypassed. We also added bypasses for the theophylline and roflumilast activities for similar reasons.
A natural extension of this work would be automatically recommend model changes to resolve
conflicts; these modifications could be regarded as implementing such recommendations.
As shown in Section 6.2 our state space exploration became impractical for large numbers of
states. The reachability graph for the OA and COPD composed model contains over 11,000 states for
some data assignments. Therefore we manually transferred the composed CPN model to CPN/Tools
[85, 86] for state space analysis, and the dead markings back to our tool for analysis. Such an
interface could be automated to allow efficient automatic state space exploration. The conflict
between NSAIDs and corticosteroid prescription was successfully discovered.
7. CONCLUSION AND FUTURE WORK
We have presented BPMN+V, a data-enriched subset of the Business Process Model and Notation
[1] (BPMN) suitable for modelling clinical guidelines. We defined a semantics for BPMN+V, based
on Workflow Graphs [36] and Coloured Petri Nets [37], which allows the effect of data upon the
guideline, and of the guideline upon the data, to be formally described. For instance, we can specify
how the valuations assigned to data attributes, such as the medications prescribed to a patient,
control the execution of activities, and how executing an activity (such as prescribing a medication),
modifies that data. We then evaluated this model using a state space analysis approach to detecting
the execution paths in two BPMN models which violate a given set of constraints.
The evaluation applied the method to artificial models, and to a real life case study using parts
of the clinical guidelines for treatment of Chronic Obstructive Pulmonary Disease (COPD) and
Osteoarthritis (OA). Using models designed in BPMN+V, the known conflicts were discovered
successfully using the state space method. Performance analysis however showed the method to
be impractical for larger models, especially those containing a high degree of parallelism (as would
often be the case in a non-prescriptive guideline). This may be addressed by integrating state of the
art state space analysis algorithms such as ASAP [87] or as implemented in CPN/Tools [86].
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In future work we plan rather to avoid state space methods, by translating BPMN+V models
into logical constraints (see e.g. [88]) to allow efficient analysis using SAT and SMT solvers such
as Alloy [38] or Z3-SMT [39]. This will allow much larger models to be efficiently analysed
and formally proved correct and complete. Whereas in the evaluations in Section 6 we designed
the constraints into the example models, in the future relevant constraints will be automatically
discovered and added to the models, using references such as the British National Formulary [42]
for medication conflicts. In consultation with clinical experts, we will define a comprehensive set of
potential conflicts, and methods to detect and recommend changes to mitigate them. These conflicts
will include medication and lifestyle, as discussed here, but also scheduling problems relating to
availability of resources such as appointments, medical personnel, and locations. Finally we plan to
build the methods into a tool suitable for use by clinicians, necessitating development of a suitable
user interface and natural language methods for inferring data and constraints from text.
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